Penumbra stock
PENNYSEPenumbra, Inc., HealthcareISIN US70975L1070
59Score 59 out of 100, Neutral
Price and trend
57 / 100
Price history
+14% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 1.6% below it.
Since August 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 44).
The price is 11% below its 52-week high. Largest decline in 11 years: 63% (April 2021 to June 2022).
Chart figures for advanced users
- SMA 50$320.15
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$325.89
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)44
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$278.10
- The lowest closing price of the last twelve months.
- Resistance$359.40
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Penumbra, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $12.64B, is number 16 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.4B (up 17.5% year on year) and earnings of $177.69M (up 1,168.1%).
- For fiscal 2026, analysts expect on average revenue of $1.6B (up 13.8%) and adjusted earnings per share of $4.66 (up 21.3%).
Show more
- MEQIRI Score 59 out of 100 (Neutral): rank 290 of 714 in Healthcare, median 53.
- The P/E is 80.9 (Medical (Devices) median 29, own median of recent years 112.2).
- Our model puts fair value at $149.46, with the price 115% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $673.61M, financial debt $209.39M.Stability 91
- Analysts expect strong earnings growthUp 20.3% a year through 2028 (estimates from 6 analysts).Growth 68
- Earnings turn into cashFree cash flow 128% of earnings over the last 12 months.Fundamentals 69
Weaknesses
- Above fair valuePrice 115% above the fair value of $149.46.Valuation 8
- Margin may fall backOperating margin 13.5%, average of the prior years 0.7%, which ranged from −6.9% to 7.2%. After peaks like this, the margin was more than a quarter lower two years later in 44 of 100 cases, against 24 of 100 for other companies with high margins.Profitability 51
Its standout strength is stability, while capital allocation and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- calm price action
Valuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $124.55 and expensive above $186.82 (uncertainty low, based on the price swings of the past year).
The two parts of the fair value come to $183.90 (cash-flow model) and $115.01 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $132.89, at 7.8% it would be $174.40.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 17% on the twelve months before. Revenue has grown strongly since 2012, at around 26% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 67%, operating 13%, net 13%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 24 Feb 2027in 104 days
- Last reported
- 29 Oct 2026EPS reported $1.07 (expected $1.20)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $4.66−2.0%
- Revenue
- $1.6B+0.4%
- Earnings per share
- $5.94−0.8%
- Revenue
- $1.81B+0.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
- Grewal HarpreetSale
2 Apr 2026, Board
- Shares
- 100
- Price
- $328.22
- Value
- $32,822
- Yuen MaggieSale
2 Mar 2026, Chief Financial Officer
- Shares
- 2,432
- Price
- $342.30
- Value
- $832,474
- Grewal HarpreetSale
6 Jan 2026, Board
- Shares
- 186
- Price
- $312.64
- Value
- $58,151
Show 5 more
- Wilder ThomasSale
2 Jan 2026, Board
- Shares
- 186
- Price
- $310.72
- Value
- $57,794
- Bose AraniSale
11 Dec 2025, Board
- Shares
- 15,000
- Price
- $308.82
- Value
- $4.63M
- Roberts JohannaSale
5 Dec 2025, EVP, Gen. Counsel & Secretary
- Shares
- 300
- Price
- $300.13
- Value
- $90,039
- Grewal HarpreetSale
2 Dec 2025, Board
- Shares
- 100
- Price
- $292.98
- Value
- $29,298
- Roberts JohannaSale
1 Dec 2025, EVP, Gen. Counsel & Secretary
- Shares
- 600
- Price
- $294.94
- Value
- $176,966
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Penumbra
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 59
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Zimmer Biomet HoldingsZBH $20.34B68
- Sonova HoldingSOON.SW $20.24B74
- GlaukosGKOS $14.63B48
- Smith & NephewSNN $12.99B67
- Align TechnologyALGN $12.13B71
- Olympus7733.T $11.7B70
- DemantDEMANT.CO $11.62B73
- InsuletPODD $10.41B65
ETFs that hold Penumbra
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.72% | 0.49% | €318.39M |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.38% | 0.30% | €5.27B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.21% | 0.43% | €2.48B |
Show 5 more
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.12% | 0.45% | €1.53B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.08% | 0.35% | €434.1M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.03% | 0.30% | €944.34M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.03% | 0.25% | €175.89M |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.01% | 0.24% | €1.69B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 1 Aug 2025)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.